HK1200164A1 - 谷氨酸的異質二聚體 - Google Patents
谷氨酸的異質二聚體Info
- Publication number
- HK1200164A1 HK1200164A1 HK15100503.3A HK15100503A HK1200164A1 HK 1200164 A1 HK1200164 A1 HK 1200164A1 HK 15100503 A HK15100503 A HK 15100503A HK 1200164 A1 HK1200164 A1 HK 1200164A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- heterodimers
- glutamic acid
- glutamic
- acid
- Prior art date
Links
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 title 1
- 235000013922 glutamic acid Nutrition 0.000 title 1
- 239000004220 glutamic acid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nuclear Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85749006P | 2006-11-08 | 2006-11-08 | |
US87867807P | 2007-01-05 | 2007-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1200164A1 true HK1200164A1 (zh) | 2015-07-31 |
Family
ID=39365345
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15100503.3A HK1200164A1 (zh) | 2006-11-08 | 2015-01-15 | 谷氨酸的異質二聚體 |
HK18116333.2A HK1257260A1 (zh) | 2006-11-08 | 2018-12-20 | 谷氨酸的異質二聚體 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18116333.2A HK1257260A1 (zh) | 2006-11-08 | 2018-12-20 | 谷氨酸的異質二聚體 |
Country Status (16)
Country | Link |
---|---|
US (11) | US20080193381A1 (zh) |
EP (5) | EP3335736B1 (zh) |
JP (2) | JP5606737B2 (zh) |
CN (2) | CN103922998A (zh) |
BR (1) | BRPI0718700B8 (zh) |
CA (1) | CA2669127C (zh) |
CY (1) | CY1116610T1 (zh) |
DK (1) | DK2097111T3 (zh) |
ES (4) | ES2547481T3 (zh) |
HK (2) | HK1200164A1 (zh) |
HU (3) | HUE039199T2 (zh) |
PL (3) | PL3699162T3 (zh) |
PT (2) | PT2097111E (zh) |
SI (1) | SI2097111T1 (zh) |
TW (1) | TWI492761B (zh) |
WO (1) | WO2008058192A2 (zh) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6528499B1 (en) | 2000-04-27 | 2003-03-04 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
EP1745802A1 (en) * | 2005-07-20 | 2007-01-24 | Kreatech Biotechnology B.V. | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
WO2008105773A2 (en) | 2006-03-31 | 2008-09-04 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
PL3699162T3 (pl) | 2006-11-08 | 2022-10-31 | Molecular Insight Pharmaceuticals, Inc. | Heterodimery kwasu glutaminowego |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
EP2136788B1 (en) * | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
WO2008124639A2 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Poly (amino acid) targeting moieties |
EP3466928A1 (en) * | 2007-06-26 | 2019-04-10 | The Johns Hopkins University | Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents |
EP3656403B1 (en) | 2007-08-17 | 2022-05-11 | Purdue Research Foundation | Preparation process of psma binding ligand-linker conjugates |
MX2010003642A (es) | 2007-10-12 | 2010-08-09 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
RU2498798C2 (ru) | 2008-01-09 | 2013-11-20 | Моликьюлар Инсайт Фармасьютикалз, Инк. | Ингибиторы карбоангидразы iх |
SI2285350T1 (en) * | 2008-06-16 | 2018-03-30 | Pfizer Inc. | Methods for the preparation of diblock copolymers functionalized with targeting agent for use in the manufacture of therapeutic nanoparticles |
JP6363320B2 (ja) | 2008-06-16 | 2018-07-25 | ファイザー・インク | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
EA020753B1 (ru) | 2008-06-16 | 2015-01-30 | Бинд Терапьютикс, Инк. | Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение |
EP4089074A1 (en) * | 2008-08-01 | 2022-11-16 | The Johns Hopkins University | Psma-binding agents and uses thereof |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
WO2010065899A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof |
BRPI0922779A8 (pt) * | 2008-12-05 | 2018-06-19 | Molecular Insight Pharm Inc | complexos de tecnécio e rênio-bis(heteroarila) e métodos de uso dos mesmos para inibir psma |
WO2010065906A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer |
US8563041B2 (en) | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
WO2010075072A2 (en) * | 2008-12-15 | 2010-07-01 | Bind Biosciences | Long circulating nanoparticles for sustained release of therapeutic agents |
AU2010249719A1 (en) | 2009-05-19 | 2012-05-31 | Aic Blab Company | Composite current collector and methods therefor |
US8465725B2 (en) | 2009-06-15 | 2013-06-18 | Molecular Insight Pharmaceuticlas, Inc. | Process for production of heterodimers of glutamic acid |
CN102596403A (zh) * | 2009-10-30 | 2012-07-18 | 住友大阪水泥股份有限公司 | 内燃机的废气净化装置 |
TR201906255T4 (tr) | 2009-12-11 | 2019-05-21 | Pfizer | Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar. |
EP2515942B1 (en) | 2009-12-15 | 2020-02-12 | Pfizer Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
EP2338892A1 (en) | 2009-12-18 | 2011-06-29 | Bayer Schering Pharma Aktiengesellschaft | Prostate specific membrane antigen inhibitors |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
JP2011206049A (ja) | 2010-03-08 | 2011-10-20 | Sumio Sugano | 壊死マーカー及びその用途 |
US10363309B2 (en) | 2011-02-04 | 2019-07-30 | Case Western Reserve University | Targeted nanoparticle conjugates |
US8926944B2 (en) * | 2011-08-05 | 2015-01-06 | Molecular Insight Pharmaceuticals | Radiolabeled prostate specific membrane antigen inhibitors |
WO2013103813A1 (en) | 2012-01-06 | 2013-07-11 | Molecular Insight Pharmaceuticals | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix |
AU2013315118B2 (en) | 2012-09-17 | 2017-10-05 | Pfizer Inc. | Process for preparing therapeutic nanoparticles |
JP6892218B2 (ja) | 2012-11-15 | 2021-06-23 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 薬物送達結合体およびpsma発現細胞によって引き起こされる疾患の治療方法 |
SG11201505477TA (en) * | 2013-01-14 | 2015-08-28 | Molecular Insight Pharm Inc | Triazine based radiopharmaceuticals and radioimaging agents |
WO2014127365A1 (en) * | 2013-02-15 | 2014-08-21 | Case Western Reserve University | Psma ligands and uses thereof |
US11975074B2 (en) | 2013-02-15 | 2024-05-07 | Case Western Reserve University | Photodynamic therapy composition |
US10207005B2 (en) | 2013-02-15 | 2019-02-19 | Case Western Reserve University | Photodynamic therapy composition |
US10434194B2 (en) | 2013-06-20 | 2019-10-08 | Case Western Reserve University | PSMA targeted nanobubbles for diagnostic and therapeutic applications |
WO2015057692A1 (en) * | 2013-10-14 | 2015-04-23 | The Johns Hopkins University | Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy |
WO2015057250A1 (en) | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
JP6908964B2 (ja) * | 2013-10-18 | 2021-07-28 | ピーエスエムエー ディベロップメント カンパニー,エルエルシー | Psmaリガンドコンジュゲートによる併用療法 |
GEP20237496B (en) | 2013-10-18 | 2023-04-10 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US20150147339A1 (en) | 2013-11-15 | 2015-05-28 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
EP3116547B1 (en) | 2014-03-14 | 2019-06-05 | Pfizer Inc | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
EP3183236B1 (en) | 2014-08-24 | 2022-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
US9956305B2 (en) | 2014-09-08 | 2018-05-01 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer |
WO2016065145A2 (en) | 2014-10-22 | 2016-04-28 | The Johns Hopkins University | Psma targeted reversed carbamates and methods of use thereof |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
US20180338910A1 (en) * | 2015-01-09 | 2018-11-29 | The Johns Hopkins University | Intranasal administration of glutamate carboxypeptidase (gcp-ii) inhibitors |
BR112018005899A2 (pt) | 2015-09-30 | 2018-10-16 | Deutsches Krebsforschungszentrum | composto e composição farmacêutica |
KR101639599B1 (ko) | 2015-11-09 | 2016-07-14 | 서울대학교산학협력단 | 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물 |
US10882871B2 (en) | 2016-01-10 | 2021-01-05 | British Columbia Cancer Agency Branch | 18/19F-labelled compounds which target the prostate specific membrane antigen |
US10829505B2 (en) | 2016-04-20 | 2020-11-10 | Dow Silicones Corporation | Lithium alkylsiliconate composition, coating, and method of making same |
FI127538B (en) * | 2016-06-22 | 2018-08-31 | Dextech Medical Ab | MODIFIED Dextran Conjugates |
CN117069621A (zh) * | 2016-06-23 | 2023-11-17 | 康奈尔大学 | 影响肿瘤杀伤的双重靶向构建体 |
CN109843338B (zh) * | 2016-06-28 | 2022-12-13 | 康奈尔大学 | 含有psma抑制剂的18f标记的三唑 |
CN117563022A (zh) | 2017-04-05 | 2024-02-20 | 康奈尔大学 | 可用于成像和抗肿瘤治疗的具有可调的药代动力学的三功能构建体 |
EP3634474A1 (en) * | 2017-06-09 | 2020-04-15 | GEMoaB Monoclonals GmbH | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders |
MX2020008247A (es) | 2018-02-06 | 2021-02-26 | Univ Johns Hopkins | Urea-poliaminocarboxilatos radiohalogenados dirigidos a antígeno prostático específico de membrana (psma) para radioterapia de cáncer. |
WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
WO2020061293A1 (en) * | 2018-09-21 | 2020-03-26 | Endocyte, Inc. | Shielding agents and their use |
CA3115806A1 (en) | 2018-10-11 | 2020-04-16 | Progenics Pharmaceuticals, Inc | Combination therapy for treating metastatic prostate cancer |
RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
WO2020139012A1 (ko) * | 2018-12-27 | 2020-07-02 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
KR20220024595A (ko) | 2019-06-21 | 2022-03-03 | 프로빈셜 헬스 서비시즈 오쏘리티 | 전립선-특이적 막 항원을 표적으로 하는 방사성표지 화합물 |
JP2023502701A (ja) * | 2019-11-21 | 2023-01-25 | フェロノヴァ プロプライエタリー リミテッド | 磁性トレーサー組成物 |
WO2021202376A1 (en) | 2020-03-30 | 2021-10-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs |
CN111548305B (zh) * | 2020-05-12 | 2021-08-31 | 北京师范大学 | 一种可用于靶向psma的喹啉类化合物及其制备方法 |
CN112209970B (zh) * | 2020-10-21 | 2021-10-29 | 北京师范大学 | 一种锝-99m标记含异腈的谷氨酸-脲衍生物的制备方法和应用 |
WO2022101352A1 (en) | 2020-11-12 | 2022-05-19 | Abx Advanced Biochemical Compounds Gmbh | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3527789A (en) * | 1967-10-06 | 1970-09-08 | Shell Oil Co | Production of poly(lower)alkyl alkenepolycarboxylates |
JP2608550B2 (ja) * | 1986-10-17 | 1997-05-07 | 株式会社 片山化学工業研究所 | 軟水ボイラの防食処理方法 |
US4888136A (en) * | 1988-05-02 | 1989-12-19 | Witco Corporation | New flame retardant compositions of matter and cellulosic products containing same |
TW353663B (en) * | 1991-04-06 | 1999-03-01 | Hoechst Ag | Process for the preparation of phosphorus-containing L-amino acids, their derivatives and intermediates for this process |
IT1270260B (it) * | 1994-06-21 | 1997-04-29 | Zambon Spa | Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi |
US6011021A (en) | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
US5795877A (en) * | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
US5902817A (en) | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
US5672592A (en) * | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
US6046180A (en) | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
US6071965A (en) * | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
US5824662A (en) * | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
US5962521A (en) | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
CA2264043A1 (en) | 1996-09-27 | 1998-04-02 | Guilford Pharmaceuticals Inc. | Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals |
ZA983930B (en) | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
DE60020962T2 (de) * | 1999-04-28 | 2006-05-24 | Georgetown University | Liganden für metabotropische Glutamat-Rezeptoren |
US6528499B1 (en) * | 2000-04-27 | 2003-03-04 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase |
US6228888B1 (en) | 1999-07-01 | 2001-05-08 | Guilford Pharmaceuticals Inc. | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
SI1472541T1 (sl) | 2002-01-10 | 2010-12-31 | Univ Johns Hopkins | Prikazovalni agensi in postopek prikazovanja naaladase ali psma |
AU2003213819C1 (en) * | 2002-03-11 | 2010-03-04 | Molecular Insight Pharmaceuticals, Inc. | Technetium-dipyridine complexes, and methods of use thereof |
ATE437239T1 (de) * | 2002-11-07 | 2009-08-15 | Newsouth Innovations Pty Ltd | Induktion der mitochondrialen permeabilitätstransition |
DE602004027631D1 (de) * | 2003-04-15 | 2010-07-22 | Mallinckrodt Inc | Bifunktionale tridentate pyrazolyl-enthaltende liganden für re-, tc- und mn- tricarbonyl-komplexe |
US7682601B2 (en) * | 2003-04-15 | 2010-03-23 | Mallinckrodt Inc. | Bifunctional tridentate pyrazolyl containing ligands for re and tc tricarbonyl complexes |
US7741510B2 (en) * | 2005-01-13 | 2010-06-22 | E. I. Du Pont De Nemours And Company | Rheology control agents |
US20060155021A1 (en) * | 2005-01-13 | 2006-07-13 | Lenges Christian P | Coating compositions containing rheology control agents |
WO2006093991A1 (en) * | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
PL3699162T3 (pl) | 2006-11-08 | 2022-10-31 | Molecular Insight Pharmaceuticals, Inc. | Heterodimery kwasu glutaminowego |
EP3466928A1 (en) * | 2007-06-26 | 2019-04-10 | The Johns Hopkins University | Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents |
EP3656403B1 (en) * | 2007-08-17 | 2022-05-11 | Purdue Research Foundation | Preparation process of psma binding ligand-linker conjugates |
WO2010108125A2 (en) | 2009-03-19 | 2010-09-23 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
US8465725B2 (en) * | 2009-06-15 | 2013-06-18 | Molecular Insight Pharmaceuticlas, Inc. | Process for production of heterodimers of glutamic acid |
US8926944B2 (en) | 2011-08-05 | 2015-01-06 | Molecular Insight Pharmaceuticals | Radiolabeled prostate specific membrane antigen inhibitors |
GEP20237496B (en) | 2013-10-18 | 2023-04-10 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US9956305B2 (en) | 2014-09-08 | 2018-05-01 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer |
-
2007
- 2007-11-07 PL PL19214298.2T patent/PL3699162T3/pl unknown
- 2007-11-07 CN CN201410158114.9A patent/CN103922998A/zh active Pending
- 2007-11-07 HU HUE15168948A patent/HUE039199T2/hu unknown
- 2007-11-07 SI SI200731686T patent/SI2097111T1/sl unknown
- 2007-11-07 ES ES07844938.6T patent/ES2547481T3/es active Active
- 2007-11-07 JP JP2009536459A patent/JP5606737B2/ja active Active
- 2007-11-07 HU HUE19214298A patent/HUE059645T2/hu unknown
- 2007-11-07 DK DK07844938.6T patent/DK2097111T3/en active
- 2007-11-07 TW TW096142019A patent/TWI492761B/zh active
- 2007-11-07 EP EP18150494.5A patent/EP3335736B1/en not_active Revoked
- 2007-11-07 EP EP15168948.6A patent/EP2942065B1/en active Active
- 2007-11-07 CN CN200780049490.2A patent/CN101778910B/zh active Active
- 2007-11-07 PL PL15168948T patent/PL2942065T3/pl unknown
- 2007-11-07 EP EP19214298.2A patent/EP3699162B1/en active Active
- 2007-11-07 EP EP21208033.7A patent/EP4023624A1/en active Pending
- 2007-11-07 CA CA2669127A patent/CA2669127C/en active Active
- 2007-11-07 PT PT78449386T patent/PT2097111E/pt unknown
- 2007-11-07 ES ES19214298T patent/ES2926912T3/es active Active
- 2007-11-07 WO PCT/US2007/083934 patent/WO2008058192A2/en active Application Filing
- 2007-11-07 PL PL07844938T patent/PL2097111T3/pl unknown
- 2007-11-07 BR BRPI0718700A patent/BRPI0718700B8/pt active IP Right Grant
- 2007-11-07 ES ES15168948.6T patent/ES2684322T3/es active Active
- 2007-11-07 ES ES18150494T patent/ES2847275T3/es active Active
- 2007-11-07 HU HUE07844938A patent/HUE026216T2/en unknown
- 2007-11-07 EP EP07844938.6A patent/EP2097111B1/en active Active
- 2007-11-07 US US11/936,659 patent/US20080193381A1/en active Granted
- 2007-11-07 PT PT192142982T patent/PT3699162T/pt unknown
-
2011
- 2011-10-12 US US13/271,549 patent/US9309193B2/en active Active
- 2011-11-11 US US13/294,677 patent/US8487129B2/en active Active
-
2014
- 2014-08-27 JP JP2014172732A patent/JP5936659B2/ja active Active
-
2015
- 2015-01-15 HK HK15100503.3A patent/HK1200164A1/zh unknown
- 2015-08-13 CY CY20151100716T patent/CY1116610T1/el unknown
-
2016
- 2016-03-14 US US15/068,841 patent/US10640461B2/en active Active
- 2016-10-28 US US15/337,867 patent/US9878980B2/en active Active
-
2017
- 2017-10-26 US US15/794,539 patent/US10131627B2/en active Active
-
2018
- 2018-10-10 US US16/156,289 patent/US10647666B2/en active Active
- 2018-12-20 HK HK18116333.2A patent/HK1257260A1/zh unknown
-
2020
- 2020-05-08 US US16/870,288 patent/US20210070695A1/en not_active Abandoned
- 2020-11-16 US US17/099,440 patent/US20210070696A1/en not_active Abandoned
-
2021
- 2021-04-23 US US17/238,535 patent/US20210246103A1/en not_active Abandoned
-
2022
- 2022-11-07 US US17/982,182 patent/US20230095637A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1257260A1 (zh) | 谷氨酸的異質二聚體 | |
BRPI0815045A2 (pt) | Composições de ácido hialurônico ajustavelmente reticuladas | |
HK1134029A1 (en) | Amino acid composition | |
PL2164349T3 (pl) | Bezproteinowa mieszanka dla niemowląt | |
HK1221220A1 (zh) | 環戊基丙烯酰胺衍生物 | |
PL2192109T3 (pl) | Bicykliczna pochodna γ-aminokwasu | |
ZA201103542B (en) | Novel composition based on gamma-hydroxybutric acid | |
ATE509925T1 (de) | Substituierte bicyclocarbonsäureamidverbindungen | |
HK1131130A1 (en) | Co-crystals of pyrrolidinones | |
GB0604899D0 (en) | Derivatives of 18-glycyrrhetinic acid | |
EP2123752A4 (en) | NOVEL NUCLEIC ACID | |
EP2077326A4 (en) | NOVEL NUCLEIC ACID | |
IL187655A0 (en) | Anthranilic acid derivatives | |
BRPI0919200A2 (pt) | derivado de aminoácido | |
BRPI0814800A2 (pt) | Derivados de aminoácidos | |
GB0602780D0 (en) | Amino Acid Derivatives | |
EP2072498A4 (en) | N-PHENYLOXAMIDE ACID DERIVATIVE | |
IL194330A0 (en) | Processes for the synthesis of 3-isobutylglutaric acid | |
ZA200808501B (en) | Acid Dyes | |
IL197506A0 (en) | Novel phenylacetic acid derivative | |
ZA200807674B (en) | Prodrugs of benzoquinolizine-2-carboxylic acid | |
GB0715712D0 (en) | Amino acid derivatives | |
EP2132171A4 (en) | NOVEL CRYSTALLINE FORMS OF PYRROLYLHEPTANOIC ACID DERIVATIVES | |
EP2013613A4 (en) | ELECTRODES BRIDGE | |
EP2128136A4 (en) | DERIVATIVE OF 2-PHENYLNICOTINIC ACID |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CORR | Corrigendum |
Free format text: CORRECTED DATA OF SECTION 20 TO JOURNAL OF 20150731: (71) MOLECULAR INSIGHT PHARMACEUTICALS, INC |